Symptoms of peripheral arterial disease: ramipril
KEYWORDS: walking, ramipril, disease, people, ahimastos, peripheral, arterial, arterial disease, peripheral arterial, reported, intermittent, intermittent claudication, claudication, evidence, summary

of angiotensin I to the vasoconstrictor angiotensin II, and preventing the breakdown of the vasodilator bradykinin (see the summary of product characteristics for Tritace). Regulatory status Ramipril is licensed for treating hypertension, renal disease and symptomatic heart failure. It is also licensed for the secondary prevention of acute myocardial infarction, and the reduction of cardiovascular morbidity and mortality in people with manifest atherothrombotic cardiovascular disease (including peripheral arterial disease) or diabetes with at least one cardiovascular risk factor. See the summary of product characteristics for Tritace for more information. The use of ramipril to treat symptoms of peripheral arterial disease is off-label. In line with the guidance from the General Medical Council (GMC), it is the responsibility of the prescriber to determine the clinical need of the patient and the suitability of using ramipril outside its authorised indications. Cost The usual dose of ramipril for licensed indications is 1.25 mg daily to 10 mg daily. For this dose range, the cost of ramipril tablets and capsules is between £1.07 and £1.33 for 28. Ramipril 2.5 mg/5 ml oral solution costs £96.00 for 150 ml (Drug Tariff, October 2015). Evidence review This evidence summary discusses 2 randomised controlled trials (RCTs) that
